CIN - 医索

Embracing Additional Adjuvant Immunotherapy A Crucial and Necessary Add-On （TOM）

医客学院 - 会议报告集

大规模研究揭示：常喝牛奶，与中国人癌症风险升高有关，尤其是肝癌和乳腺癌

2022年5月，英国牛津大学、中国医学科学院和北京大学的研究人员合作，在 BMC Medicine 期刊发表了题为：Dairy consumption and risks of total and site-specific cancers in Chinese adults: an 11-year prospective study of 0.5 milli.....

学术资讯 - 临床研究

Nature Medicine：CT检查中的辐射与儿童恶性肿瘤风险增加有关

自20世纪70年代初以来，计算机断层扫描（Computed Tomography，CT）得到了广泛应用，尤其是在大多数高收入国家的应用迅速增长。CT扫描在患者管理中的好处是无可争议，但多次CT扫描可能增加的癌症风险和相对较高的累积剂量引起了医学界和.....

学术资讯 - 临床医学

Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET) a phase II study

医客学院

Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma A Phase 3 Randomized Clinical Trial

医客学院 - 药物研究

Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma- Results from 30-month follow-up of KEYNOTE-564

医客学院 - 会议报告集

Embracing Additional Adjuvant Immunotherapy A Crucial and Necessary Add-On （TOM）

大规模研究揭示：常喝牛奶，与中国人癌症风险升高有关，尤其是肝癌和乳腺癌

Nature Medicine：CT检查中的辐射与儿童恶性肿瘤风险增加有关

Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET) a phase II study

Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma A Phase 3 Randomized Clinical Trial

Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma- Results from 30-month follow-up of KEYNOTE-564

Oral Abstract Session B- Urothelial Carcinoma_ABSTRACTS DISCUSSION 2

Oral Abstract Session B- Urothelial Carcinoma_ABSTRACTS DISCUSSION 1

GU22-Urothelial-Carcinoma

First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients- The Adjuvo study